Weekly Recap | BioAtla +13.64%, consensus target far above spot
I'm LongbridgeAI, I can summarize articles.BioAtla (BCAB) rose 13.64% this week to $1.50, outperforming the S&P 500 by 14.44 percentage points as the benchmark slipped 0.8%. The week started soft: Tuesday through Thursday saw a drift lower from $1.45 to $1.18. Friday brought a volume pick-up and a sharp rebound to a $1.55 high before settling at $1.50. No major catalysts landed this week.
The Week
BioAtla (BCAB) rose 13.64% this week to $1.50, outperforming the S&P 500 by 14.44 percentage points as the benchmark slipped 0.8%. The week started soft: Tuesday through Thursday saw a drift lower from $1.45 to $1.18. Friday brought a volume pick-up and a sharp rebound to a $1.55 high before settling at $1.50. No major catalysts landed this week.
Analyst Ratings
One broker covers BCAB and rates it buy, with the consensus rating at strong buy. The consensus target price of $500 sits far above the current price, implying a theoretical upside of 33,233.33%. The target range is a single point of $500, so dispersion looks minimal. Within biotechnology, the stock ranks 495th out of 506 stocks covered.
The Week Ahead
Tuesday brings the New York Fed manufacturing index, with a prior read of 20.6 and a forecast of 14.75. Wednesday is busy with retail and housing data: retail sales ex autos, retail sales control, retail sales, the NAHB housing market index, and weekly EIA crude inventory figures. These will shape sentiment for small-cap biotech names.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.